Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM, Oravecz-Wilson KI, Concel VJ, Hess EM, Van Beek M, Delekta PC, Gu S, Watkins SC, Ting AT, Gough PJ, Foley KP, Bertin J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2016 Sep 27;17(1):221-32. doi: 10.1016/j.celrep.2016.08.080.

2.

API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis.

Rosebeck S, Lim MS, Elenitoba-Johnson KS, McAllister-Lucas LM, Lucas PC.

World J Biol Chem. 2016 Feb 26;7(1):128-37. doi: 10.4331/wjbc.v7.i1.128. Review.

3.

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla SL, Lee AV, Oesterreich S.

Clin Cancer Res. 2016 Mar 1;22(5):1130-7. doi: 10.1158/1078-0432.CCR-15-1534. Epub 2015 Oct 23.

4.

Non-Hematopoietic β-Arrestin1 Confers Protection Against Experimental Colitis.

Lee T, Lee E, Arrollo D, Lucas PC, Parameswaran N.

J Cell Physiol. 2016 May;231(5):992-1000. doi: 10.1002/jcp.25216. Epub 2015 Nov 20.

5.

Protective Role of β-arrestin2 in Colitis Through Modulation of T-cell Activation.

Sharma D, Malik A, Steury MD, Lucas PC, Parameswaran N.

Inflamm Bowel Dis. 2015 Dec;21(12):2766-77. doi: 10.1097/MIB.0000000000000563.

6.

Molecular drivers of lobular carcinoma in situ.

Logan GJ, Dabbs DJ, Lucas PC, Jankowitz RC, Brown DD, Clark BZ, Oesterreich S, McAuliffe PF.

Breast Cancer Res. 2015 Jun 4;17:76. doi: 10.1186/s13058-015-0580-5. Review.

7.

Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.

Markó L, Henke N, Park JK, Spallek B, Qadri F, Balogh A, Apel IJ, Oravecz-Wilson KI, Choi M, Przybyl L, Binger KJ, Haase N, Wilck N, Heuser A, Fokuhl V, Ruland J, Lucas PC, McAllister-Lucas LM, Luft FC, Dechend R, Müller DN.

Hypertension. 2014 Nov;64(5):1032-9. doi: 10.1161/HYPERTENSIONAHA.114.03900. Epub 2014 Sep 2.

8.

Nonhematopoietic β-Arrestin-1 inhibits inflammation in a murine model of polymicrobial sepsis.

Sharma D, Packiriswamy N, Malik A, Lucas PC, Parameswaran N.

Am J Pathol. 2014 Aug;184(8):2297-309. doi: 10.1016/j.ajpath.2014.05.002. Epub 2014 Jun 17.

9.

The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling.

Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM.

Oncogene. 2014 May 8;33(19):2520-30. doi: 10.1038/onc.2013.195. Epub 2013 Jun 17.

10.

β-Arrestin-1 deficiency protects mice from experimental colitis.

Lee T, Lee E, Irwin R, Lucas PC, McCabe LR, Parameswaran N.

Am J Pathol. 2013 Apr;182(4):1114-23. doi: 10.1016/j.ajpath.2012.12.025. Epub 2013 Feb 8.

11.

Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance.

Van Beek M, Oravecz-Wilson KI, Delekta PC, Gu S, Li X, Jin X, Apel IJ, Konkle KS, Feng Y, Teitelbaum DH, Ruland J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2012 May 31;1(5):444-52.

12.

MALT1 protease: a new therapeutic target in B lymphoma and beyond?

McAllister-Lucas LM, Baens M, Lucas PC.

Clin Cancer Res. 2011 Nov 1;17(21):6623-31. doi: 10.1158/1078-0432.CCR-11-0467. Epub 2011 Aug 25. Review.

13.

From MALT lymphoma to the CBM signalosome: three decades of discovery.

Rosebeck S, Rehman AO, Lucas PC, McAllister-Lucas LM.

Cell Cycle. 2011 Aug 1;10(15):2485-96. Epub 2011 Aug 1. Review.

14.

Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment.

Rosebeck S, Lucas PC, McAllister-Lucas LM.

Future Oncol. 2011 May;7(5):613-7. doi: 10.2217/fon.11.35. Review.

15.

Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis.

Okawada M, Koga H, Larsen SD, Showalter HD, Turbiak AJ, Jin X, Lucas PC, Lipka E, Hillfinger J, Kim JS, Teitelbaum DH.

Dig Dis Sci. 2011 Sep;56(9):2553-65. doi: 10.1007/s10620-011-1651-9. Epub 2011 Mar 12.

16.

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.

Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM.

Science. 2011 Jan 28;331(6016):468-72. doi: 10.1126/science.1198946. Erratum in: Science. 2011 Apr 22;332(6028):421.

17.

Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome.

Delekta PC, Apel IJ, Gu S, Siu K, Hattori Y, McAllister-Lucas LM, Lucas PC.

J Biol Chem. 2010 Dec 31;285(53):41432-42. doi: 10.1074/jbc.M110.158949. Epub 2010 Nov 1.

18.

The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, Delekta PC, Van Beek M, Lucas PC.

J Biol Chem. 2010 Aug 20;285(34):25880-4. doi: 10.1074/jbc.C110.109421. Epub 2010 Jul 5.

19.

Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.

Oravecz-Wilson KI, Philips ST, Yilmaz OH, Ames HM, Li L, Crawford BD, Gauvin AM, Lucas PC, Sitwala K, Downing JR, Morrison SJ, Ross TS.

Cancer Cell. 2009 Aug 4;16(2):137-48. doi: 10.1016/j.ccr.2009.06.007.

20.

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM.

Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10284-9. doi: 10.1073/pnas.0900351106. Epub 2009 Jun 1.

Supplemental Content

Loading ...
Support Center